Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) and Alphatec (NASDAQ:ATEC – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.
Profitability
This table compares Treace Medical Concepts and Alphatec’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Treace Medical Concepts | -28.99% | -71.37% | -30.49% |
| Alphatec | -13.49% | -6,752.24% | -13.88% |
Valuation and Earnings
This table compares Treace Medical Concepts and Alphatec”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Treace Medical Concepts | $212.69 million | 1.24 | -$59.00 million | ($0.93) | -4.34 |
| Alphatec | $764.16 million | 2.11 | -$143.36 million | ($0.71) | -14.70 |
Treace Medical Concepts has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Treace Medical Concepts and Alphatec, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Treace Medical Concepts | 2 | 4 | 1 | 0 | 1.86 |
| Alphatec | 1 | 1 | 13 | 0 | 2.80 |
Treace Medical Concepts presently has a consensus target price of $5.17, indicating a potential upside of 27.97%. Alphatec has a consensus target price of $17.40, indicating a potential upside of 66.67%. Given Alphatec’s stronger consensus rating and higher possible upside, analysts clearly believe Alphatec is more favorable than Treace Medical Concepts.
Volatility & Risk
Treace Medical Concepts has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
Institutional & Insider Ownership
84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 66.3% of Alphatec shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by company insiders. Comparatively, 13.5% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Alphatec beats Treace Medical Concepts on 8 of the 13 factors compared between the two stocks.
About Treace Medical Concepts
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
About Alphatec
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.
